Karen Joy Shaw, Ph.D., is chief scientific officer at Amplyx and was previously the company’s vice president of biology. She joins Amplyx from Hearts Consulting Group, where she provided consulting services for infectious disease drug discovery and development, natural products, technology evaluation, and antibacterial and antifungal drug discovery. She also served as senior vice president of biology at Trius Therapeutics (acquired by Cubist Pharmaceuticals). At Trius, she was on the team that developed the antibiotic tedizolid phosphate (Sivextro®), and she presented the drug’s microbiology and pharmacology to the FDA advisory board committee. Her work there also led to the creation of a novel class of broad spectrum antimicrobial agents. Prior to joining Trius, Dr. Shaw was team leader for the infectious diseases unit at Johnson & Johnson Pharmaceutical Research & Development, where she developed bacterial microarray technology for E. coli and S. aureus as well as a novel bacterial RNA amplification technology; the combination enabled the first simultaneous microarray analysis of host and pathogen interactions during an in vivo infection resulting in the identification of key responses. Karen Joy Shaw, Ph.D., is chief scientific officer at Amplyx and was previously the company’s vice president of biology. She joins Amplyx from Hearts Consulting Group, where she provided consulting services for infectious disease drug discovery and development, natural products, technology evaluation, and antibacterial and antifungal drug discovery. She also served as senior vice president of biology at Trius Therapeutics (acquired by Cubist Pharmaceuticals). At Trius, she was on the team that developed the antibiotic tedizolid phosphate (Sivextro®), and she presented the drug’s microbiology and pharmacology to the FDA advisory board committee. Her work there also led to the creation of a novel class of broad spectrum antimicrobial agents. Prior to joining Trius, Dr. Shaw was team leader for the infectious diseases unit at Johnson & Johnson Pharmaceutical Research & Development, where she developed bacterial microarray technology for E. coli and S. aureus as well as a novel bacterial RNA amplification technology; the combination enabled the first simultaneous microarray analysis of host and pathogen interactions during an in vivo infection resulting in the identification of key responses.

Business